Sign in to view content

Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2021

Related

An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration
Keyvan Koushan, MD, FRCSC
Annual Meeting Talks
2023
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020

Category: AMD-Neovascular

See more